IMAC Holdings, Inc.

Overview

• IndustryServices-Specialty Outpatient Facilities, NEC²
• HeadquartersBrentwood, United States²
• Incorporated inDE³
• Business address3401 Mallory Lane, Suite 100, Franklin, Tn 37067³
• Filer categoryNon-accelerated filer, Smaller reporting company³
• Legal formCorporation²
• LEI549300TXY4OF7MHCTD62²
• StatusActive²
• LEI statusLapsed (not renewed)²
• Registered addressC/O National Registered Agents, Inc., 19904 Dover, United States²
• Registered withDivision of Corporations, Department of State, 6898979²

See how the biggest companies compare on our leaderboards

HER2-driven pathway activation and signaling coherence. The study is published at https://pmc.ncbi.nlm.nih.gov/articles/PMC8571284/.⁴ From its latest annual report

Corporate structure

IMAC Holdings, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What IMAC Holdings, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

Investments

Properties, in its own words

We manage our business operations from our principal executive office in Franklin, Tennessee and laboratory space in Golden, Colorado. We are in the process of having the lease for the laboratory space we use in Golden, Colorado assigned to us. Our executive office lease and our laboratory lease are on a month-to-month basis. Our total rent expense was $0.1 million under our office and laboratory lease for 2024.

We believe our present office space are adequate for our current operations.

Item 2 of the 10-K filed Apr 15, 2025.⁴

Leadership

Who has led IMAC Holdings, Inc., and when. Pick a name to see everywhere that person has worked.

• Chief executive officerFaith Zaslavsky May 31, 2024 to May 31, 2024¹⁴
• Chief executive officerJeffrey S. Ervin Feb 15, 2019 to May 25, 2022¹⁵
• Chief financial officerSheri Gardzina Jun 5, 2020 to May 25, 2022¹⁶
• Chief financial officerDwight Anthony Bond Feb 15, 2019 to Feb 15, 2019¹⁷
• Chief operating officerMatthew C. Wallis Feb 21, 2019 to Apr 9, 2021¹⁸

Named in SEC Form D filings

People the company listed in its private-offering notices.

• Executive OfficerBen C. Lerner named Aug 25, 2022²⁸

Former names

• IMAC HOLDINGS LLCMar 16, 2018 to Aug 9, 2018³

Timeline

1. Mar 19, 20268-K Entered a material agreement; Unregistered sale of shares²⁹
2. Feb 27, 20268-K Entered a material agreement; New debt or obligation³⁰
3. Feb 18, 20268-K Entered a material agreement; New debt or obligation³¹
4. Jan 30, 20268-K Entered a material agreement; New debt or obligation³²
5. Jan 16, 20268-K Entered a material agreement; New debt or obligation³³
6. Dec 30, 20258-K Entered a material agreement; New debt or obligation; Unregistered sale of shares³⁴
7. Dec 29, 20258-K Entered a material agreement; New debt or obligation³⁵
8. Dec 16, 20258-K Entered a material agreement; New debt or obligation³⁶
9. Dec 1, 20258-K Entered a material agreement; New debt or obligation³⁷
10. Nov 20, 20258-K Entered a material agreement; New debt or obligation³⁸
11. Oct 31, 20258-K Entered a material agreement; New debt or obligation³⁹
12. Oct 20, 20258-K Entered a material agreement; New debt or obligation⁴⁰
13. May 31, 2024New chief executive Faith Zaslavsky becomes CEO¹⁴
14. Feb 15, 2019New chief executive Jeffrey S. Ervin becomes CEO¹⁵

Filings

208 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 93 major events, 32 insider forms, 8 large holders, 2 private raises, 52 other. The latest 20:

1. Mar 31, 202615-12G EDGAR
2. Mar 19, 20268-K EDGAR
3. Feb 27, 20268-K EDGAR
4. Feb 18, 20268-K EDGAR
5. Jan 30, 20268-K EDGAR
6. Jan 16, 20268-K EDGAR
7. Dec 30, 20258-K EDGAR
8. Dec 29, 20258-K EDGAR
9. Dec 17, 202510-Q EDGAR
10. Dec 16, 20258-K EDGAR
11. Dec 1, 20258-K EDGAR
12. Nov 20, 20258-K EDGAR
13. Nov 14, 2025NT 10-Q EDGAR
14. Oct 31, 20258-K EDGAR
15. Oct 20, 20258-K EDGAR
16. Oct 3, 20258-K EDGAR
17. Sep 18, 20258-K EDGAR
18. Sep 10, 20258-K EDGAR
19. Aug 19, 20258-K EDGAR
20. Aug 14, 202510-Q EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

5 open-market trades by officers, directors and large owners since October 2021: 2 buys and 3 sales. Grants, option exercises and gifts are left out.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

• Jorge RuizSCHEDULE 13G/A, 2 filings Mar 13, 2025 to Mar 18, 2025⁴¹
• ALPHA CAPITAL ANSTALTSC 13G/A, 2 filings Jan 19, 2022 to Feb 7, 2023⁴²
• Peter S. LynchSC 13G, 2 filings May 18, 2022 to Jan 23, 2023⁴³
• Nantahala Capital Management, LLCSC 13G/A, 2 filings Feb 14, 2022 to Sep 9, 2022⁴⁴

Money raised

Private offerings the company reported to the SEC on Form D.

1. Apr 11, 2024Raised $900,000 in a private offering of equity Form D: $5.4 million offered in all Form D
2. Aug 16, 2022Raised $3.9 million in a private offering of securities Form D: 12 investors so far Form D

SEC filer profile

How IMAC Holdings, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

• Name on EDGARIMAC Holdings, Inc.¹
• CIK0001729944
• Employer ID (EIN)83-0784691⁴
• Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; a shell company⁴
• Incorporated inDelaware⁴
• Fiscal year endsDecember 31¹
• Industry code (SIC)8093 Services-Specialty Outpatient Facilities, NEC¹
• SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance¹
• Business address3401 Mallory Lane, Suite 100, Franklin, TN 37067¹
• Phone844-266-4622¹
• Shares outstanding3,784,966 as of Dec 16, 2025¹²
• Public float$3.1M as of Jun 30, 2024⁴
• AuditorMarcum LLP, New York, NY PCAOB ID 688; no auditor attestation of internal control over financial reporting⁴
• On EDGAR sinceMar 16, 2018¹
• Filings357 in all: 8-K (123), 4 (57), 10-Q (21), 3 (17), S-1/A (17), CORRESP (16), NT 10-Q (8), UPLOAD (8)¹
  All 42 form types

  10-K (7), 424B5 (6), DEF 14A (6), EFFECT (6), SC 13G (6), DEFA14A (5), PRE 14A (5), 8-K/A (4), NT 10-K (4), S-1 (4), SC 13G/A (4), D (3), S-4/A (3), 10-K/A (2), 10-Q/A (2), 25-NSE (2), 424B4 (2), FWP (2), S-3 (2), 15-12G (1), 424B3 (1), 425 (1), 5 (1), 8-A12B (1), CERT (1), DRS (1), DRS/A (1), RW (1), S-3/A (1), S-4 (1), S-8 (1), SC 13D (1), SCHEDULE 13G (1), SCHEDULE 13G/A (1)

• Latest filingsAnnual report (10-K) Apr 15, 2025
  Quarterly report (10-Q) Dec 17, 2025
  Proxy statement (DEF 14A) Feb 11, 2025
  Latest 8-K (8-K) Mar 19, 2026

Securities registered for trading

From the cover page of the 10-K filed Apr 15, 2025 (Section 12(b) of the Exchange Act).⁴

Risk factors and legal proceedings

The risks IMAC Holdings, Inc. names in Item 1A of its 10-K filed Apr 15, 2025: 31 risks under these headings, as written.⁴

• Risks Relating to Our Business
• We recorded a net loss for the years ended December 31, 2024 and December 31, 2023 and there can be no assurance that our future operations will result in net income; we received a going concern qualification.
• If we are unable to successfully integrate the assets we purchased from Theralink, our financial results could be adversely affected.
• We may fail completely to implement key elements of our growth and expansion strategy, which could adversely affect our operations and financial performance.
• If we fail to achieve and sustain commercial success for our services, our business will suffer, our future prospects may be harmed, and our stock price would likely decline.
• Our competitors may develop and market products that are less expensive, more effective, safer or reach the market sooner, which may diminish or eliminate the commercial success of any products we may commercialize.
• Many universities and private and public research institutes may in the future become active in cancer research, which may be in direct competition with us.
• We could face competition from other technologies and products that could impact our profitability.
• We must rely on relationships with third-party suppliers to supply necessary resources used in our technology. These relationships are not easy to replace.
• Our prospective revenues will be diminished if payors do not adequately cover or reimburse our services.
• We are susceptible to risks relating to investigation or audit by the Centers for Medicare & Medicaid Services (“CMS”), health insurance providers and the IRS.
• Regulatory changes, such as proposed government regulation of LDTs, could require us to conduct additional clinical trials or result in delays, increased costs, or the failure to obtain necessary regulatory approvals, which could harm our business.

Legal proceedings

Lincoln Gardens Partners, LLC d/b/a Twin Lakes Office Park (“Landlord”), filed a complaint against the Company, IMAC Management of Florida (“IMAC Florida”), and Mr. Marty Willmitch on March 14, 2025 in the Circuit Court of the Thirteenth Judicial Circuit, in and for Hillsborough County, Florida relating to an alleged default in a foreclosure action regarding a lease by Landlord of the Company’s former clinic location in Tampa, Florida. The Company has surrendered the premises and is in discussions with the Landlord regarding outstanding amounts and a potential settlement. The Landlord alleges that the Company may owe approximately $0.15 million for accelerated lease payments, commissions, costs of tenant improvements, and interest owed in accordance with certain lease agreements.

From time to time, we may become involved in various lawsuits and legal proceedings that arise in the ordinary course of our business. Litigation is, however, subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business. We are currently not aware of any legal proceedings or claims that we believe would or could have, individually or in the aggregate, a material adverse effect on us. Regardless of final outcomes, however, any such proceedings or claims may nonetheless impose a significant burden on management and employees and may come with costly defense costs or unfavorable preliminary interim rulings. Refer to Note 12, Commitments and Contingencies, to our Consolidated Financial Statements included in “Part II, Item 8. Financial Statements” of this Form 10-K for a description of current legal proceedings.

The opening of Item 3, Legal Proceedings.⁴